ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation has a strategic partnership for healthy aging research with the Jiangxi Provincial Government, the People’s Republic of China. ChromaDex Corporation is based in Irvine, California.

  • Edited Transcript of CDXC earnings conference call or presentation 9-May-19 8:30pm GMT
    on May 20, 2019 at 2:25 am

    Q1 2019 Chromadex Corp Earnings Ca […]

  • ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference
    on May 15, 2019 at 8:01 pm

    ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. […]

  • ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript
    on May 13, 2019 at 5:18 pm

    CDXC earnings call for the period ending March 31, 2019. […]

  • ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
    on May 9, 2019 at 10:45 pm

    ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? […]

  • ChromaDex: 1Q Earnings Snapshot
    on May 9, 2019 at 9:38 pm

    The Los Angeles-based company said it had a loss of 15 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The natural products company posted revenue of $10 million in ... […]

  • ChromaDex Corporation Reports First Quarter 2019 Financial Results
    on May 9, 2019 at 8:01 pm

    - First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net. […]

  • ChromaDex Announces $10 Million Issuance of Convertible Notes
    on May 9, 2019 at 12:20 pm

    ChromaDex Corp. (CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The convertible notes will automatically convert into shares of ChromaDex common stock 45 days following the closing.  The convertible notes will convert at $4.59 per share (market closing price on May 7, 2019), or if a common stock financing occurs in the 45 day period following the closing with a purchase price of less than $4.59 per share, at the price per share at which shares are issued in that financing. […]

  • Should You Be Concerned About ChromaDex Corporation's (NASDAQ:CDXC) Historical Volatility?
    on May 7, 2019 at 3:13 pm

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in ChromaDex Corporation (NASDAQ:CDXC), then you might want to consider its beta... […]

  • Will ChromaDex (CDXC) Report Negative Q1 Earnings? What You Should Know
    on May 2, 2019 at 2:32 pm

    ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. […]

  • ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
    on May 2, 2019 at 10:30 am

    LOS ANGELES, May 02, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its. […]

New agreement gives @NestleHealthUS
exclusive rights to use #TruNiagen by @ChromaDex
in #medical food products.

Read more:

What’s So Special About Nicotinamide Riboside?
An FAQ with Dr. @CharlesMBrenner The scientist who uncovered #NR’s potential discusses why this #nutrient is so unique.

New @truniagen PRO Launched for Expansive Distribution by Healthcare Practitioners

ChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health

ChromaDex to Launch TRU NIAGEN® in New Zealand with Retail Partner #Matakana SuperFoods

Load More...


What's Your Role?*



Company Description*



ChromaDex Corporation

10005 Muirlands Boulevard
Suite G
Irvine, CA 92618

+1 (949) 419-0288

May 2019
« Apr    

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account